Barclays raised the firm’s price target on Labcorp (LH) to $290 from $275 and keeps an Equal Weight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp partners with Roche to advance digital pathology capabilities
- Labcorp Holdings to Release Q3 2025 Financial Results
- Labcorp Holdings to Join Morgan Stanley Healthcare Conference
- Labcorp price target raised to $311 from $302 at Baird
- Labcorp launches first FDA-cleared blood test for Alzheimer’s disease